ACUERDO 029 CRES PDF

Home  /   ACUERDO 029 CRES PDF

Por medio del Acuerdo de , la Comisión de Regulación en Salud – CRES-, introdujo ajustes al Acuerdo , por medio del cual se. acuerdo de cres pdf. Quote. Postby Just» Tue Aug 28, am. Looking for acuerdo de cres pdf. Will be grateful for any help! Top. P P 11 1 P(|racu|ra |loslalo) 15 rd de oase lao|ela o cápsu|a. P Z0 1 0u|r|ra d|c|o(r|d(alo rd/2 rL so|uc|ór |rveclao|e. P 10 1 0u|r|ra.

Author: Vutaxe Tygogal
Country: Congo
Language: English (Spanish)
Genre: Technology
Published (Last): 21 November 2007
Pages: 313
PDF File Size: 17.7 Mb
ePub File Size: 17.80 Mb
ISBN: 788-9-37051-490-7
Downloads: 64959
Price: Free* [*Free Regsitration Required]
Uploader: Meztilkis

It has been shown that quality-of-care improvement programs for patients with metabolic disorders can achieve great changes and reduce complications through effective therapy The above findings support increasing the dose of the lipid-lowering therapy based on clearly defined objectives 16, Lipid concentrations and the use of lipid lowering drugs: For risk group 1, the average dose of lovastatin was higher in the controlled patients than in the uncontrolled 74 vs.

In risk group 5, the average dose of gemfibrozil was greater in the controlled patients than in the acuerdk 2 vs. Clinicians should proactively identify patients at high risk of heart disease and treat them aggressively according to the desired lipid level target, 09 with statins, and then by adding other crew if necessary Controlled versus uncontrolled dyslipidemic patients For risk group 1, the average dose of lovastatin was higher in the controlled patients than in the uncontrolled 74 vs.

acuerdo 029 de 2011 cres pdf

It was found that the prevalence of aspirin use as a prophylaxis of cardiovascular risk was higher than that reported by other studies Colombia has adopted an essential drugs list into the Plan Obligatorio de Salud Mandatory Health Plan, POS ; initially it included three generic agents for dyslipidemia management: In cases Most patients in the present study had other risk factors that increased the difficulty of dyslipidemia management and control, especially for asymptomatic diseases, such as hypertension, diabetes, and hypothyroidism; and the use of additional medications for each of these problems results in patients with polypharmacy, as reported by another study Cardiovascular disease and lipids.

  GNUSTEP TUTORIAL PDF

Prescription patterns for antilipidemic drugs in a group of Colombian patients. Also of note is that the entire sample of patients received generic drugs. It is disconcerting that only This can be correlated with a lack of knowledge on the part of many physicians around what is a desirable goal based on the patient’s risk and what drug and dose should be prescribed to reach it Effectiveness and tolerability of ezetimibe co-administered with statins versus statin dose-doubling in high-risk patients with persistent hyperlipidemia: Therapy adherence was determined by the degree to which the patient complied with the recommendations recorded by the doctor in the medical record.

In this study, however, the proportion of patients who claim to have followed the correct treatment was relatively high, which is in contrast to the low rate of metabolic control There was no statistical significance with the following variables: This was a cross-sectional retrospective study of patients who were: Ministry of Health, Colombia.

Under these circumstances, strategies aimed at identifying individuals with dyslipidemia and implementing primary and secondary CVD preventive measures have become health priorities. Differences between clinical trial efficacy and real-world effectiveness.

Controlled versus uncontrolled dyslipidemic patients. Primatesta P, Poulter RN.

Resultado de busqueda | Consultorsalud

Arterioscler Thromb Vasc Biol. A difference was found between the 0029 and final LDL-C levels despite the statistically-significant reduction percentages, which are lower than those reported for lovastatin by other studies 4.

Am J Manag Care. However, with high doses of this drug, the values are quite close to the results of one study 6. Given that multiple studies have documented that hypercholesterolemia increases the risk of developing CVD, its control has become a goal of physicians 1.

There was a problem providing the content you requested

Consejo Nacional de Seguridad Social en Salud. Mean differences were determined by a nonparametric test i. Sample size calculation and power analysis: Several associated factors were also examined: The present study evaluated the effectiveness of lipid-lowering therapies in dislipidemic patients affiliated with the SGSSS.

  BAL SAMAY RAVI BHAKSH LIYO TAB PDF

Effectiveness of lipid-lowering therapy among a sample of patients in Colombia. Effects of Quality Improvement Strategies for type 2 diabetes on glycemic control. Table 2 shows the results of the bivariate analysis that compared the subgroup of patients whose total-C was controlled versus the uncontrolled subgroup.

In cases where the target LDL-C level was not being met, and if all patients are considered to have complied with the adjustments, then therapy modifications were insufficient 19, Unfortunately, dyslipidemia treatment meets the three conditions that are associated with poor adherence: Models of binary logistic regression were applied using the LDL-C and triglyceride levels as the dependent variable, and variables that were significantly-associated with the dependent variable were considered covariables in the bivariate analysis.

It has even been suggested that a suboptimal statin treatment may increase the risk of coronary events The quality of the patient records was reviewed by two physicians.

acuerdo de cres pdf – PDF Files

Diario Oficial de Colombia. In the patients comprising risk group 1, The reasons for this discrepancy may include using a lower dose than recommended, problems with treatment adherence, and a lack of medical management goals 19, 24, Detection, evaluation, and treatment of high blood cholesterol in adults. In risk group 2, the average dose of lovastatin was lower in the controlled patients than in the uncontrolled 62 vs.